Filing Flows › Boston Scientific (BSX) › Q2 2026 › vs Q1 2026
Boston Scientific (BSX) Q2 2026 vs Q1 2026 (quarter over quarter)
Boston Scientific's revenue rose $239M (+5%) from $5.2B in Q1 2026 to $5.4B in Q2 2026. The biggest changes: Interventional Cardiology & Vascular Therapies +$89.0M (+7%); Endoscopy +$57.0M (+8%); Urology +$38.0M (+6%). Gross margin 70.7% against 69.5% (+1.2 pts).
Boston Scientific, Q2 2026: revenue $5.4B (+8% year over year), operating margin 21.6%, net earnings $905M, operating cash flow $1.5B. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Gross margin | 70.7% | 69.5% | +1.2 pts |
| Operating margin | 21.6% | 21.2% | +0.5 pts |
| Net margin | 16.6% | 25.7% | -9.1 pts |
| Free cash flow margin | 23.5% | 3.3% | +20.2 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Interventional Cardiology & Vascular Therapies | $1.3B | $1.2B | $89.0M | +7% |
| Electrophysiology | $916M | $905M | $11.0M | +1% |
| Endoscopy | $793M | $736M | $57.0M | +8% |
| Urology | $684M | $646M | $38.0M | +6% |
| Cardiac Rhythm Management | $585M | $578M | $7.0M | +1% |
| Watchman | $507M | $506M | $1.0M | +0.2% |
| Neuromodulation | $341M | $318M | $23.0M | +7% |
| Interventional Oncology & Embolization | $283M | $268M | $15.0M | +6% |
| Revenue | $5.4B | $5.2B | $239M | +5% |
| Gross profit | $3.8B | $3.6B | $234M | +6% |
| Cost of revenue | $1.6B | $1.6B | $5.0M | +0.3% |
| Operating profit | $1.2B | $1.1B | $77.0M | +7% |
| Operating expenses | $2.7B | $2.5B | $157M | +6% |
| Pre-tax earnings | $1.1B | $1.2B | −$102M | -9% |
| Other expense, net | $118M | −$61.0M | $179M | — |
| Research & development | $554M | $516M | $38.0M | +7% |
| SG&A | $1.8B | $1.8B | $22.0M | +1% |
| Other operating costs | $313M | $216M | $97.0M | +45% |
| Net earnings | $905M | $1.3B | −$434M | -32% |
| Income tax | $155M | −$176M | $331M | — |
| Depreciation & amortization | $355M | $351M | $4.0M | +1% |
| Share-based compensation | $87.0M | $83.0M | $4.0M | +5% |
| Working capital & other | $127M | −$1.4B | $1.6B | — |
| Operating cash flow | $1.5B | $348M | $1.1B | +324% |
| Free cash flow (OCF − capex) | $1.3B | $171M | $1.1B | +648% |
| Capital expenditures | $195M | $177M | $18.0M | +10% |
Questions
How much did Boston Scientific's revenue grow quarter over quarter in Q2 2026?
Boston Scientific's revenue rose $239M (+5%) from $5.2B in Q1 2026 to $5.4B in Q2 2026.
What drove Boston Scientific's revenue change in Q2 2026?
Interventional Cardiology & Vascular Therapies +$89.0M (+7%); Endoscopy +$57.0M (+8%); Urology +$38.0M (+6%).